Metaxalone Formulation Using Surfactant and Polymer Excipients
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Metaxalone formulations face challenges with low aqueous solubility, leading to slow absorption and incomplete bioavailability, along with a significant food effect, which can result in higher doses and side effects such as CNS depression, nausea, and hepatotoxicity.
Innovation Solution
A metaxalone formulation comprising metaxalone or its pharmaceutically acceptable salt, sodium lauryl sulfate, hydroxypropyl methylcellulose (HPMC), and a copolymer of vinylpyrrolidone and vinyl acetate, which improves solubility, bioavailability, and reduces the food effect, allowing for faster onset of action.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If conventional metaxalone formulations are used, then the drug can be administered, but the aqueous solubility is poor leading to slow absorption and incomplete bioavailability
Solution Approach 1:
The patent applies parameter changes by modifying the physical state of metaxalone from crystalline to amorphous form, and by changing the formulation parameters to include specific excipients (sodium lauryl sulfate, HPMC, vinylpyrrolidone-vinyl acetate copolymer) in optimized ratios. These parameter changes dramatically improve aqueous solubility and absorption rate while maintaining dosage control.
Solution Approach 2:
The patent creates a composite material system by combining metaxalone with multiple excipients (sodium lauryl sulfate as surfactant, HPMC as polymer matrix, vinylpyrrolidone-vinyl acetate copolymer as solubility enhancer) in a specific formulation. This composite approach synergistically improves solubility, stability, and bioavailability beyond what single components could achieve.
2Reliability
If higher doses of metaxalone are administered to compensate for incomplete bioavailability, then the therapeutic effect may be improved, but side effects such as CNS depression, nausea, and hepatotoxicity increase
Solution Approach 1:
The patent introduces intermediary substances (surfactants and polymers) that mediate between the poorly soluble metaxalone and the aqueous gastrointestinal environment. Sodium lauryl sulfate acts as a surfactant intermediary to enhance wetting and dissolution, while HPMC and the copolymer serve as solubility-enhancing intermediaries, allowing effective drug delivery at lower doses with reduced side effects.
3Loss of time
If the formulation is designed to improve solubility and bioavailability, then the onset of action can be faster, but the formulation complexity increases
Solution Approach 1:
The patent applies preliminary action by pre-processing metaxalone into an amorphous state and pre-formulating it with solubility-enhancing excipients before administration. This preliminary preparation ensures rapid dissolution and absorption upon contact with gastrointestinal fluids, achieving fast onset of action. The formulation complexity is managed by establishing standardized manufacturing processes for the amorphous dispersion.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves improved solubility and bioavailability, with enhanced pharmacokinetic parameters like Cmax and tmax, reducing the need for higher doses and minimizing side effects, while maintaining effective treatment of musculoskeletal conditions.
Implementation Method 1
sodium lauryl sulfate
Implementation Method 2
hydroxypropyl methylcellulose (HPMC)
Implementation Method 3
a copolymer of vinylpyrrolidone and vinyl acetate
Data Source
AI summary
The invention provides a pharmaceutical composition comprising sodium lauryl sulfate, hydroxypropyl methylcellulose (HPMC), a copolymer of vinylpyrrolidone and vinyl acetate, and a therapeutically effective amount of metaxalone or a pharmaceutically acceptable salt thereof. Related processes and methods are also disclosed.